Anika Therapeutics (ANIK) Competitors $14.95 +0.04 (+0.27%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$14.95 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIK vs. ANVS, QDEL, CERS, OSUR, and UTMDShould you buy Anika Therapeutics stock or one of its competitors? MarketBeat compares Anika Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anika Therapeutics include Annovis Bio (ANVS), QuidelOrtho (QDEL), Cerus (CERS), OraSure Technologies (OSUR), and Utah Medical Products (UTMD). These companies are all part of the "medical" sector. ANIK vs. ANVSANIK vs. QDELANIK vs. CERSANIK vs. OSURANIK vs. UTMDHow does Anika Therapeutics compare to Annovis Bio?Anika Therapeutics (NASDAQ:ANIK) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation. Do analysts prefer ANIK or ANVS? Anika Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 13.71%. Annovis Bio has a consensus target price of $13.50, indicating a potential upside of 555.66%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts plainly believe Annovis Bio is more favorable than Anika Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do insiders & institutionals have more ownership in ANIK or ANVS? 91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor ANIK or ANVS? In the previous week, Annovis Bio had 1 more articles in the media than Anika Therapeutics. MarketBeat recorded 2 mentions for Annovis Bio and 1 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 0.00 beat Annovis Bio's score of -1.50 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Negative Is ANIK or ANVS more profitable? Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -9.52%. Anika Therapeutics' return on equity of -5.90% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Anika Therapeutics-9.52% -5.90% -4.52% Annovis Bio N/A -253.99%-205.55% Which has more risk and volatility, ANIK or ANVS? Anika Therapeutics has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Which has higher valuation and earnings, ANIK or ANVS? Anika Therapeutics has higher revenue and earnings than Annovis Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnika Therapeutics$116.26M1.71-$10.88M-$0.79N/AAnnovis BioN/AN/A-$28.85M-$1.71N/A SummaryAnnovis Bio beats Anika Therapeutics on 8 of the 15 factors compared between the two stocks.How does Anika Therapeutics compare to QuidelOrtho?QuidelOrtho (NASDAQ:QDEL) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk. Does the media prefer QDEL or ANIK? In the previous week, QuidelOrtho had 4 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for QuidelOrtho and 1 mentions for Anika Therapeutics. QuidelOrtho's average media sentiment score of 0.33 beat Anika Therapeutics' score of 0.00 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, QDEL or ANIK? QuidelOrtho has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Do insiders and institutionals hold more shares of QDEL or ANIK? 99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 0.8% of QuidelOrtho shares are owned by insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable valuation & earnings, QDEL or ANIK? Anika Therapeutics has lower revenue, but higher earnings than QuidelOrtho. Anika Therapeutics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuidelOrtho$2.66B0.28-$1.13B-$17.82N/AAnika Therapeutics$116.26M1.71-$10.88M-$0.79N/A Is QDEL or ANIK more profitable? Anika Therapeutics has a net margin of -9.52% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat Anika Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets QuidelOrtho-45.57% 4.25% 1.56% Anika Therapeutics -9.52%-5.90%-4.52% Do analysts rate QDEL or ANIK? QuidelOrtho presently has a consensus price target of $14.88, suggesting a potential upside of 37.22%. Anika Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 13.71%. Given QuidelOrtho's higher probable upside, equities research analysts plainly believe QuidelOrtho is more favorable than Anika Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QuidelOrtho 3 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryQuidelOrtho beats Anika Therapeutics on 9 of the 16 factors compared between the two stocks.How does Anika Therapeutics compare to Cerus?Cerus (NASDAQ:CERS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Which has more volatility & risk, CERS or ANIK? Cerus has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Is CERS or ANIK more profitable? Cerus has a net margin of -4.41% compared to Anika Therapeutics' net margin of -9.52%. Anika Therapeutics' return on equity of -5.90% beat Cerus' return on equity.Company Net Margins Return on Equity Return on Assets Cerus-4.41% -15.18% -4.38% Anika Therapeutics -9.52%-5.90%-4.52% Do analysts prefer CERS or ANIK? Cerus presently has a consensus price target of $4.00, suggesting a potential upside of 64.61%. Anika Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 13.71%. Given Cerus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cerus is more favorable than Anika Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerus 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer CERS or ANIK? In the previous week, Cerus and Cerus both had 1 articles in the media. Cerus' average media sentiment score of 0.75 beat Anika Therapeutics' score of 0.00 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, CERS or ANIK? Anika Therapeutics has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCerus$206.13M2.36-$15.63M-$0.05N/AAnika Therapeutics$116.26M1.71-$10.88M-$0.79N/A Do insiders & institutionals hold more shares of CERS or ANIK? 78.4% of Cerus shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 3.4% of Cerus shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryCerus beats Anika Therapeutics on 10 of the 15 factors compared between the two stocks.How does Anika Therapeutics compare to OraSure Technologies?OraSure Technologies (NASDAQ:OSUR) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends. Do insiders & institutionals have more ownership in OSUR or ANIK? 93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 3.9% of OraSure Technologies shares are owned by insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend OSUR or ANIK? OraSure Technologies presently has a consensus target price of $3.00, indicating a potential downside of 0.33%. Anika Therapeutics has a consensus target price of $17.00, indicating a potential upside of 13.71%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Anika Therapeutics is more favorable than OraSure Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OraSure Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is OSUR or ANIK more profitable? Anika Therapeutics has a net margin of -9.52% compared to OraSure Technologies' net margin of -66.42%. Anika Therapeutics' return on equity of -5.90% beat OraSure Technologies' return on equity.Company Net Margins Return on Equity Return on Assets OraSure Technologies-66.42% -18.57% -15.71% Anika Therapeutics -9.52%-5.90%-4.52% Does the media refer more to OSUR or ANIK? In the previous week, OraSure Technologies had 6 more articles in the media than Anika Therapeutics. MarketBeat recorded 7 mentions for OraSure Technologies and 1 mentions for Anika Therapeutics. OraSure Technologies' average media sentiment score of 1.02 beat Anika Therapeutics' score of 0.00 indicating that OraSure Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OraSure Technologies 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, OSUR or ANIK? Anika Therapeutics has higher revenue and earnings than OraSure Technologies. Anika Therapeutics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOraSure Technologies$115.02M1.80-$68.73M-$1.04N/AAnika Therapeutics$116.26M1.71-$10.88M-$0.79N/A Which has more volatility and risk, OSUR or ANIK? OraSure Technologies has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. SummaryAnika Therapeutics beats OraSure Technologies on 10 of the 16 factors compared between the two stocks.How does Anika Therapeutics compare to Utah Medical Products?Utah Medical Products (NASDAQ:UTMD) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation. Which has more risk & volatility, UTMD or ANIK? Utah Medical Products has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Do insiders and institutionals have more ownership in UTMD or ANIK? 69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 8.0% of Utah Medical Products shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is UTMD or ANIK more profitable? Utah Medical Products has a net margin of 28.90% compared to Anika Therapeutics' net margin of -9.52%. Utah Medical Products' return on equity of 9.13% beat Anika Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Utah Medical Products28.90% 9.13% 8.86% Anika Therapeutics -9.52%-5.90%-4.52% Does the media refer more to UTMD or ANIK? In the previous week, Utah Medical Products had 2 more articles in the media than Anika Therapeutics. MarketBeat recorded 3 mentions for Utah Medical Products and 1 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 0.00 beat Utah Medical Products' score of -0.20 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utah Medical Products 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend UTMD or ANIK? Anika Therapeutics has a consensus price target of $17.00, indicating a potential upside of 13.71%. Given Anika Therapeutics' higher probable upside, analysts clearly believe Anika Therapeutics is more favorable than Utah Medical Products.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable valuation and earnings, UTMD or ANIK? Utah Medical Products has higher earnings, but lower revenue than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUtah Medical Products$38.52M5.28$11.29M$3.3818.93Anika Therapeutics$116.26M1.71-$10.88M-$0.79N/A SummaryUtah Medical Products beats Anika Therapeutics on 9 of the 15 factors compared between the two stocks. Get Anika Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIK vs. The Competition ExportMetricAnika TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$198.39M$3.31B$6.25B$12.29BDividend YieldN/A2.34%2.80%5.31%P/E Ratio-18.9218.1320.6325.23Price / Sales1.71289.71552.0079.35Price / CashN/A55.2727.4837.30Price / Book1.506.579.676.63Net Income-$10.88M$24.35M$3.56B$335.59M7 Day Performance1.84%-2.53%-1.65%-1.20%1 Month Performance-6.56%-3.55%-2.61%-1.16%1 Year Performance22.94%53.51%30.05%28.10% Anika Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIKAnika Therapeutics2.9669 of 5 stars$14.95+0.3%$17.00+13.7%+22.6%$198.39M$116.26MN/A300Positive NewsANVSAnnovis Bio1.9437 of 5 stars$2.40+5.0%$13.50+463.7%+15.0%$79.00MN/AN/A3Earnings ReportQDELQuidelOrtho3.359 of 5 stars$9.96-7.8%$14.88+49.3%-67.6%$736.46M$2.73BN/A6,500CERSCerus2.5125 of 5 stars$2.52-3.4%$4.00+58.7%+82.7%$522.96M$206.13MN/A290Positive NewsOSUROraSure Technologies2.2494 of 5 stars$3.02-1.3%$3.00-0.7%+23.9%$220.21M$115.02MN/A840 Related Companies and Tools Related Companies Annovis Bio Alternatives QuidelOrtho Alternatives Cerus Alternatives OraSure Technologies Alternatives Utah Medical Products Alternatives West Pharmaceutical Services Alternatives Align Technology Alternatives Cooper Companies Alternatives Merit Medical Systems Alternatives ICU Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIK) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
